Ixazomib Improves Progression-Free Survival in Relapsed, Refractory Multiple Myeloma
the Cancer Therapy Advisor take:
Takeda Pharmaceutical Company Limited has announced that the double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 study assessing the efficacy and safety of ixazomib for the treatment of patients with relapsed or refractory multiple myeloma achieved its primary endpoint of improving progression-free survival at an interim analysis. Ixazomib is an investigational oral proteasome inhibitor being studied in various malignancies.
For the study, researchers enrolled 722 adult patients with relapsed or refractory multiple myeloma and randomly assigned them to receive ixazomib plus lenalidomide and dexamethasone or placebo plus lenalidomide and dexamethasone.
All participants had received between one and three prior therapies, and no patients refractory to lenalidomide or proteasome inhibitor-based therapy were included.
Ixazomib is the first oral proteasome inhibitor, but is in the same class of drugs as bortezomib and carfilzomib. It is currently being evaluated in four Phase 3 studies for the treatment of relapsed or refractory multiple myeloma, relapsed or refractory systemic light-chain amyloidosis, newly diagnosed multiple myeloma, and as maintenance therapy in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem cell transplantation.
Ixazomib for the treatment of relapsed or refractory multiple myeloma achieved its primary endpoint.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed